Autoimmune Diseases  >>  Sylvant (siltuximab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sylvant (siltuximab) / Jazz
NCT02641522: Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes

Completed
1
10
US
Siltuximab, Sylvant
Carla Greenbaum, MD, Janssen Research & Development, LLC
Type 1 Diabetes
03/17
03/17

Download Options